Geode Capital Management, Llc reports 12.19% increase in ownership of CYX / Cardlytics, Inc.

Cardlytics, Inc.

DE ˙ DB ˙ US14161W1053

0,45 € ↓ -0,04 (-8,23%)

2026-06-05
DEL PRIS

Security	DE:CYX / Cardlytics, Inc.
Institution	Geode Capital Management, Llc
Latest Disclosed Ownership	734,232 shares
Latest Disclosed Value	$ 771,164

On May 15, 2026 - Geode Capital Management, Llc filed a 13F-HR form disclosing ownership of 734,232 shares of Cardlytics, Inc. (DE:CYX) valued at $543,772 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 654,472 shares of Cardlytics, Inc.. This represents a change in shares of 12.19% during the quarter. The current value of the position is $327,467 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	CARDLYTICS	COM	14161W105	734,232	79,760	12.19	771	2.53	0.0000
2026-02-09	2025-12-31	13F	CARDLYTICS	COM	14161W105	654,472	20,908	3.30	753	-51.17	0.0000
2025-11-12	2025-09-30	13F	CARDLYTICS	COM	14161W105	633,564	1,003	0.16	1,540	48.08	0.0001
2025-08-08	2025-06-30	13F	CARDLYTICS	COM	14161W105	632,561	-482,500	-43.27	1,041	-48.74	0.0001
2025-05-13	2025-03-31	13F	CARDLYTICS	COM	14161W105	1,115,061	54,322	5.12	2,030	-48.45	0.0002
2025-02-12	2024-12-31	13F	CARDLYTICS	COM	14161W105	1,060,739	7,561	0.72	3,936	16.80	0.0003
2024-11-12	2024-09-30	13F	CARDLYTICS	COM	14161W105	1,053,178	73,484	7.50	3,371	-58.11	0.0003
2024-08-09	2024-06-30	13F	CARDLYTICS	COM	14161W105	979,694	132,997	15.71	8,045	-34.44	0.0007
2024-05-13	2024-03-31	13F	CARDLYTICS	COM	14161W105	846,697	22,474	2.73	12,270	61.64	0.0011
2024-02-13	2023-12-31	13F	CARDLYTICS	COM	14161W105	824,223	79,751	10.71	7,592	-38.21	0.0008
2023-11-13	2023-09-30	13F	CARDLYTICS	COM	14161W105	744,472	65,855	9.70	12,285	186.50	0.0015
2023-08-11	2023-06-30	13F	CARDLYTICS	COM	14161W105	678,617	39,887	6.24	4,289	97.79	0.0005
2023-05-15	2023-03-31	13F	CARDLYTICS	COM	14161W105	638,730	14,066	2.25	2,168	72,166.67	0.0003
2023-02-13	2022-12-31	13F	CARDLYTICS	COM	14161W105	624,664	26,769	4.48	4	-99.95	0.0005
2022-11-14	2022-09-30	13F	CARDLYTICS	COM	14161W105	597,895	-15,843	-2.58	5,620	-58.95	0.0009
2022-08-12	2022-06-30	13F	CARDLYTICS	COM	14161W105	613,738	17,914	3.01	13,692	-58.20	0.0020
2022-05-13	2022-03-31	13F	CARDLYTICS	COM	14161W105	595,824	25,941	4.55	32,758	-13.02	0.0041
2022-02-11	2021-12-31	13F	CARDLYTICS	COM	14161W105	569,883	24,467	4.49	37,663	-17.73	0.0045
2021-11-12	2021-09-30	13F	CARDLYTICS	COM	14161W105	545,416	-6,672	-1.21	45,782	-34.67	0.0062
2021-08-13	2021-06-30	13F	CARDLYTICS	COM	14161W105	552,088	46,452	9.19	70,076	26.34	0.0097
2021-05-12	2021-03-31	13F	CARDLYTICS	COM	14161W105	505,636	85,621	20.39	55,468	-7.50	0.0085
2021-02-12	2020-12-31	13F	CARDLYTICS	COM	14161W105	420,015	22,524	5.67	59,965	113.78	0.0101
2020-11-13	2020-09-30	13F	CARDLYTICS	COM	14161W105	397,491	39,522	11.04	28,050	11.98	0.0055
2020-08-13	2020-06-30	13F	CARDLYTICS	COM	14161W105	357,969	60,898	20.50	25,050	141.21	0.0054
2020-05-14	2020-03-31	13F	CARDLYTICS	COM	14161W105	297,071	55,930	23.19	10,385	-31.49	0.0027
2020-02-20	2019-12-31	13F/A-1	CARDLYTICS	COM	14161W105	241,141	29,644	14.02	15,158	113.82	0.0032
2020-02-13	2019-12-31	13F	CARDLYTICS	COM	14161W105	241,141	29,644		15,158		1,931.7542
2019-11-12	2019-09-30	13F	CARDLYTICS	COM	14161W105	211,497	30,411	16.79	7,089	50.70	0.0017
2019-08-14	2019-06-30	13F	CARDLYTICS	COM	14161W105	181,086	66,432	57.94	4,704	148.10	0.0011
2019-05-14	2019-03-31	13F	CARDLYTICS	COM	14161W105	114,654	34,638	43.29	1,896	118.94	0.0005
2019-03-06	2018-12-31	13F/A-1	CARDLYTICS	COM	14161W105	80,016	5,610	7.54	866	-53.52	0.0003
2019-02-13	2018-12-31	13F	CARDLYTICS	COM	14161W105	80,016	5,610		866
2018-11-13	2018-09-30	13F	CARDLYTICS	COM	14161W105	74,406	18,759	33.71	1,863	53.97	0.0005
2018-08-14	2018-06-30	13F	CARDLYTICS	COM	14161W105	55,647	10,136	22.27	1,210	81.95	0.0004
2018-05-15	2018-03-31	13F	CARDLYTICS	COM	14161W105	45,511	45,511		665		0.0002

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.